Biogen Cuts Expansion Plan for Tecfidera and Tysabri

[roxanne]

According to a recent article in the Boston Globe, Biogen is discontinuing its clinical late stage trials for expanding the use of Tecfidera and Tysabri to secondary progressive ms. So you RR's are all set but we SP's are out of luck. Again.
It seems that poor Biogen is on pace this year to earn only $5 BILLION on Tecfidera instead of a projected $7B. (Biogen has already earned $965.6 in this last third quarter). They have cut 880 jobs - including researchers among others.
So Biogen has just discontinued the trials. Poof! Just like that!
On the bright side, however, the company plans to continue development of another ms drug that could repair nerve damage rather than just slow progression. If it ever comes to fruition, lets all hope that not only is it effective, but that it makes money!

[Kimba22]

Thanks for sharing this with us, just wish it was better news for Secondary Progessive MS and research! Here's the article for anyone interested: https://www.bostonglobe.com/business...2QJ/story.html And as much as those high profits may bother us, making money off our disease is the bottom line for the pharmaceutical companies.

Here's a clip from the recent ECTRIMS conference about their their hopeful remylination drug, anti-Lingo-1: http://msworld.org/conference-center...-remyelination

[timeuponaonce]

Anti-Lingo-1 looks promising.

Thanks Kimba for posting the video. Anti-Lingo-1 looks promising.

I noticed that Biogen is the company investing in the Anti-Lingo-1 clinical trial. And from the recent Boston Globe article above, it seems that Biogen is using the savings from retrenchment to invest in new drug candidates, including a drug that could repair nerve damage in MS patients. Let's hope some of these new drugs work well to help reverse our MS and improve our lives.

Time